BRPI0210549B8 - antimaláricos de espiro e dispiro 1,2,4-trioxolano - Google Patents

antimaláricos de espiro e dispiro 1,2,4-trioxolano

Info

Publication number
BRPI0210549B8
BRPI0210549B8 BRPI0210549A BRPI0210549B8 BR PI0210549 B8 BRPI0210549 B8 BR PI0210549B8 BR PI0210549 A BRPI0210549 A BR PI0210549A BR PI0210549 B8 BRPI0210549 B8 BR PI0210549B8
Authority
BR
Brazil
Prior art keywords
spiro
trioxolane
antimalarials
group
spirocyclohexyl
Prior art date
Application number
Other languages
English (en)
Inventor
Matile Hugues
Chollet Jacques
L Vennerstrom Jonathan
Padmanilayam Maniyan
N Charman William
Tang Yuanqing
Dong Yuxiang
Original Assignee
Medicines Malaria Venture Mmv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicines Malaria Venture Mmv filed Critical Medicines Malaria Venture Mmv
Publication of BR0210549A publication Critical patent/BR0210549A/pt
Publication of BRPI0210549B1 publication Critical patent/BRPI0210549B1/pt
Publication of BRPI0210549B8 publication Critical patent/BRPI0210549B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

antimaláricos de espiro e dispiro 1,2,4-trioxolano são descritos um meio e método para tratamento de malária, esquistossomíase e câncer utilizando um espiro ou dispiro 1,2,4-trioxolano. os 1,2,4-trioxolanos preferidos incluem um grupo de espiroadamantano em um lado do grupo de trioxolano e uma espirocicloexila no outro lado do grupo de trioxolano, pelo que o anel de espirocicloexila é de preferência substituído na posição-4. em comparação com derivados semi-sintéticos de artemisinina, os compostos da presente invenção são estruturalmente simples, fáceis de sintetizar, não tóxicos e potentes contra parasitas maláricos.
BR0210549-7 2001-06-21 2002-06-21 antimaláricos de espiro e dispiro 1,2,4-trioxolano BRPI0210549B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/886.666 2001-06-21
US09/886,666 US6486199B1 (en) 2001-06-21 2001-06-21 Spiro and dispiro 1,2,4-trioxolane antimalarials
PCT/US2002/019767 WO2003000676A1 (en) 2001-06-21 2002-06-21 1,2,4-trioxolane antimalarials

Publications (3)

Publication Number Publication Date
BR0210549A BR0210549A (pt) 2005-01-11
BRPI0210549B1 BRPI0210549B1 (pt) 2020-11-10
BRPI0210549B8 true BRPI0210549B8 (pt) 2021-05-25

Family

ID=25389491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210549-7 BRPI0210549B8 (pt) 2001-06-21 2002-06-21 antimaláricos de espiro e dispiro 1,2,4-trioxolano

Country Status (24)

Country Link
US (1) US6486199B1 (pt)
EP (1) EP1414813B1 (pt)
JP (1) JP4303585B2 (pt)
KR (1) KR100759144B1 (pt)
CN (1) CN1545508B (pt)
AT (1) ATE339411T1 (pt)
AU (1) AU2002327183B2 (pt)
BR (1) BRPI0210549B8 (pt)
CA (1) CA2451006C (pt)
CY (1) CY1106214T1 (pt)
DE (1) DE60214733T8 (pt)
DK (1) DK1414813T3 (pt)
ES (1) ES2271323T3 (pt)
HU (1) HUP0400246A3 (pt)
IL (1) IL159474A0 (pt)
MX (1) MXPA03011915A (pt)
NO (1) NO20035721L (pt)
PL (1) PL226418B1 (pt)
PT (1) PT1414813E (pt)
RU (1) RU2271357C2 (pt)
SI (1) SI1414813T1 (pt)
UA (1) UA78709C2 (pt)
WO (1) WO2003000676A1 (pt)
YU (1) YU100703A (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536887T1 (de) * 2002-06-06 2011-12-15 Univ Washington Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
FR2862304A1 (fr) * 2003-11-14 2005-05-20 Centre Nat Rech Scient Molecules duales racemiques ou achirales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
US20080275112A1 (en) * 2004-07-23 2008-11-06 Schreiner Peter R Invention Concerning Aminoadamantane Compounds
US20060040761A1 (en) * 2004-08-23 2006-02-23 Sam-Kyu Shin Scale mark mat for putting practice
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
PL1898901T3 (pl) 2005-05-18 2017-07-31 Sun Pharmaceutical Industries Limited Stabilne postacie dawkowania spiro i dispiro 1, 2, 4-trioksolanowych związków przeciwmalarycznych
WO2007036947A1 (en) * 2005-09-30 2007-04-05 Ipca Laboratories Limited Delayed release anti-malarial composition
ATE464301T1 (de) 2005-10-04 2010-04-15 Director General Defence Res & Aus gomphostemma niveum isolierte verbindung gegen malaria
WO2007112451A2 (en) * 2006-03-28 2007-10-04 University Of Washington Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
JP2009533368A (ja) 2006-04-11 2009-09-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
AP2525A (en) * 2006-05-17 2012-12-05 Ranbaxy Lab Ltd Antimarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative
SI2029569T1 (sl) * 2006-05-24 2013-03-29 Ranbaxy Laboratories Limited Postopek za pripravo dispiro-1,2,4-trioksolanskega protimalarijskega sredstva (OZ277 soli)
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
GB0619333D0 (en) * 2006-09-30 2006-11-08 Univ Liverpool Dispiro tetraoxane compounds
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
FR2924343A1 (fr) * 2007-12-04 2009-06-05 Palumed Sa Nouvelles utilisations therapeutiques de molecules duales contenant un derive peroxydique.
WO2010001824A1 (ja) * 2008-07-01 2010-01-07 国立大学法人 岡山大学 新規抗住血吸虫剤
US8618096B2 (en) 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
MX2014000463A (es) 2011-07-14 2014-07-09 Ranbaxy Lab Ltd Formas de dosificacion estables de aterolane y piperaquina.
WO2015123595A1 (en) 2014-02-14 2015-08-20 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
AU2015370911B2 (en) 2014-12-23 2020-07-09 Bergenbio Asa Inhibitors of Akt kinase
RU2601315C1 (ru) * 2015-06-10 2016-11-10 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения пентаоксаспироалканов
WO2019005977A1 (en) * 2017-06-27 2019-01-03 The Regents Of The University Of California TRIOXOLANE AGENTS
CN108424371B (zh) * 2018-01-19 2021-07-16 北京理工大学 2-(4-氨基环己基)-乙酸乙酯的制备方法
US20210386814A1 (en) * 2020-05-20 2021-12-16 Amanuel Tesfazion Methods and compound for the treatment of malaria

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621062A (en) 1966-10-25 1971-11-16 Sterling Drug Inc 2-(8-cyclohexyloctanoyl or 7-cyclohexylheptanoyl)-1-naphthol
US3673222A (en) 1969-11-26 1972-06-27 Sydney Archer 2-(8-cyclohexyloctyl or 7-cyclohexylheptyl)-1,4-naphthoquinone and process for preparation and use thereof
US3682991A (en) 1970-10-19 1972-08-08 Sterling Drug Inc 3,3,5-trimethylcyclohexyl-alkyl-carboxylic acids
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4816478A (en) 1987-08-24 1989-03-28 Thornfeldt Carl R Treatment of acquired immunodeficiency syndrome
US5053342A (en) 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
US5270344A (en) 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
JP2867529B2 (ja) 1990-01-22 1999-03-08 三菱電機株式会社 投写型表示装置
US5216175A (en) 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5219880A (en) 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5510356A (en) 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
US5171676A (en) 1991-10-31 1992-12-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of introducing hydroxyl groups into artemisinin and its derivatives
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
ATE152630T1 (de) 1992-07-28 1997-05-15 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5780675A (en) 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5578637A (en) 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5817692A (en) 1995-11-22 1998-10-06 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5672624A (en) 1995-11-22 1997-09-30 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5932591A (en) 1996-12-02 1999-08-03 Johns Hopkins University C3 substituted trioxanes useful as antiparasitic drugs

Also Published As

Publication number Publication date
NO20035721D0 (no) 2003-12-19
HUP0400246A2 (hu) 2004-08-30
CN1545508A (zh) 2004-11-10
RU2004101409A (ru) 2005-06-10
CA2451006C (en) 2011-08-23
NO20035721L (no) 2004-02-23
ATE339411T1 (de) 2006-10-15
DK1414813T3 (da) 2007-01-02
ES2271323T3 (es) 2007-04-16
AU2002327183C1 (en) 2003-01-08
AU2002327183B2 (en) 2006-03-09
DE60214733T2 (de) 2007-09-13
EP1414813A1 (en) 2004-05-06
PL226418B1 (pl) 2017-07-31
CN1545508B (zh) 2012-06-06
IL159474A0 (en) 2004-06-01
UA78709C2 (en) 2007-04-25
BRPI0210549B1 (pt) 2020-11-10
KR20040030697A (ko) 2004-04-09
CY1106214T1 (el) 2011-06-08
DE60214733T8 (de) 2008-02-21
MXPA03011915A (es) 2004-05-21
KR100759144B1 (ko) 2007-09-14
BR0210549A (pt) 2005-01-11
PL367158A1 (en) 2005-02-21
US6486199B1 (en) 2002-11-26
EP1414813B1 (en) 2006-09-13
RU2271357C2 (ru) 2006-03-10
YU100703A (sh) 2006-03-03
JP4303585B2 (ja) 2009-07-29
JP2004535436A (ja) 2004-11-25
DE60214733D1 (de) 2006-10-26
WO2003000676A1 (en) 2003-01-03
PT1414813E (pt) 2006-12-29
HUP0400246A3 (en) 2009-12-28
SI1414813T1 (sl) 2006-12-31
CA2451006A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
BRPI0210549B8 (pt) antimaláricos de espiro e dispiro 1,2,4-trioxolano
CY1117133T1 (el) Ανθελονοσιακα δισπειρο-1,2,4-τριοξολανιων
NO20060044L (no) Fremgangsmate for fremstilling av substituerte 3-aryl-butyl-aminforbindelser
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
BR0316883A (pt) Derivado de piridazin-3(2h)-ona, composto, processo para a preparação de um composto composição farmacêutica, uso do composto, método para o tratamento de um sujeito que está sofrendo de uma condição patológica ou doença susceptìvel de melhora por meio de inibição da fosfodiesterase 4 e produto de combinação
CY1115148T1 (el) Ανθελονοσιακα δισπειρο 1,2,4-τριοξολανια
WO2009091433A3 (en) Spiro and dispiro 1,2,4-trioxolane antimalarials
EE200300397A (et) Epotilooni derivaadid refraktaarsete kasvajate raviks
ATE359786T1 (de) Camptothecin derivate
BR0209936A (pt) Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk
DE69904282T2 (de) Verwendung von Chromane und/oder Chromene Derivaten zur Vermeidung von freien Radikalen induzierten oxidativen Reaktionen
NO20042936L (no) Nye krystallinske former av meloksikam og fremgangsmater for deres fremstilling og interkonversjon
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
BRPI0414632A (pt) composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase 3, de uma doença ou condição, e de distúrbios relacionados aos ossos, processo para a preparação de um composto, e, uso de intermediários
AR022588A1 (es) Derivados de mevinolina
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
BR9914811A (pt) Processo para a preparação de derivados de quercetina e isoquercetina
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
BR0208221A (pt) Combinação de uma taxano e uma cinase dependente de ciclina
DK0906303T3 (da) Ringannellerede dihydropyraner, fremgangsmåde til deres fremstilling samt anvendelse deraf
WO2003070159A3 (en) Novel coumarin and chromene compounds and methods of treating or preventing viral infections
WO2003028652A3 (en) Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
NO20041537L (no) Fremgangsmate ved fremstilling av 14beta-hydroksy-baccatin III-1, 14-karbonat
NO20041542L (no) Fremgangsmate ved fremstilling av 14 beta-hydroksy-baccatin III-1,14-karbonat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2728 DE 18-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.